In addition, EZH2 is positively correlated with MSI‐H or TMB in pan‐cancer,[40, 41, 42] indicating a greater therapeutic potential for EZH2 inhibitors as well as higher sensitivity to immunotherapy, thereby further implying the rationality of the combination approach. Here, EZH2 is linked to cancer.